结肠癌CapeOX方案新辅助化疗的临床研究  

The clinical efficacy of neoadjuvant chemotherapy using oxaliplatin and capecitabine in the treatment of advanced colon cancer

作　　者：孙春花[1] 徐晓俊[1] 过雪丹[1] 赵帆[1] 

机构地区：[1]无锡市第二人民医院肿瘤科,江苏无锡214002

出　　处：《中国肿瘤外科杂志》2015年第6期387-389,393,共4页Chinese Journal of Surgical Oncology

摘　　要：目的分析结肠癌CapeOX(奥沙利铂+卡培他滨)方案新辅助化疗的疗效、不良反应。方法从无锡市第二人民医院中筛选2010年1月至2012年12月确诊的52例晚期结肠癌患者,随机均分为两组。试验组采用奥沙利铂+卡培他滨(CapeOX),对照组采用奥沙利铂+氟尿嘧啶(mFOLFOX)。观察两组的疗效和毒副作用。结果两组患者各完成3个疗程的化疗后,试验组客观有效率达57.69%,优于对照组的23.07%,且差异具有统计学意义(P<0.05);试验组患者出现白细胞减少及肝功能异常等不良反应少于对照组,差异具有统计学意义(P<0.05)。结论 CapeOX方案新辅助化疗用于晚期结肠癌的疗效好,不良反应轻。Objective To investigate the clinical efficacy and adverse reactions during neoadjuvant chemo- therapy using oxaliplatin and capecitabine in the treatment of advanced colon cancer patients. Methods From January 2010 to December 2012, 52 advanced colon cancer patients in WUxi No. 2 hospital were selected and di- vided into 2 group at random. The experimental group was given the combination therapy of oxaliplatin and capecitabine, while the control group was treated with oxaliplatin and 5-FU. Results The objective response rate after 3 course of treatment in the experimental group was 57.69%, which was better than 23.07% in the control group, and the difference was statistically significant（P 〈 O. 05） ;the occurrence of leucopenia and liver function abnormality in the experimental group was statistically decreased compared with that of the control group, and the difference was statistically significant （P 〈 0.05）. Conclusions The combination application of oxaliplatin and capecitabine has better therapeutic effect and fewer adverse reactions for treating advanced colon cancer.

关 键 词：结肠肿瘤 新辅助化疗 奥沙利铂 卡培他滨 氟尿嘧啶 

分 类 号：R735.35[医药卫生—肿瘤]